Caitlyn Krebs is a biotech executive with over 20 years of experience advancing therapeutics, diagnostics, and digital health innovations. She is the Co-Founder and CEO of Nalu Bio, where she leads the development of next-generation cannabinoid-inspired therapeutics with pharmaceutical-grade quality and scalability. Over her career, Caitlyn has completed more than 50 strategic partnerships and product launches across biopharma, diagnostics, and digital health.

Nalu Bio recently announced positive results for a cannabinoid-based therapeutic for endometriosis, a condition that affects 200 million women worldwide.

During our conversation, we discussed:

• Understanding Endometriosis – symptoms, diagnosis, and current treatment options
• How Millions of women with endometriosis are using CBD or THC to self-treat symptoms
• What makes the endocannabinoid system a prime target for for endometriosis
• How Nalu Bio uses an AI platform to accelerate the development of novel, consistent, and non-addictive cannabinoid molecules
• The potential for broader applications for cannabinoid-based therapeutics, similar to GLP-1 therapies

The timeline for future clinical trials and potential FDA-approval

Thanks to This Episode’s Sponsor: The Society of Cannabis Clinicians

The Society of Cannabis Clinicians’ Med Cann conference offers a rare opportunity for clinicians to dive deep into the clinical realities and therapeutic potential of medical cannabis and psychedelics. Designed with healthcare providers in mind, their sessions focus on case-based learning, emerging protocols, and real-world challenges—offering practical insights that can be immediately applied in your practice.

Learn more at cannabisclinicians.org and use code “CP15” to receive 15% Off Your Registration

Additional Resources

• NaluBio.com
• Big Data Begins to Crack the Case of Endometriosis (UCSF)
• CannMed Call for Abstracts